A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Clinical trial NCT00715403 · COMPLETED
Trial details
- NCT number
- NCT00715403
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2004-10-01
- Primary completion
- 2009-09-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.